

Project title	<p><i>Joint Working Project between Sandwell and West Birmingham NHS Trust and Sanofi to improve identification and management of high-risk cardiovascular patients with cardiovascular disease and primary hypercholesterolaemia / mixed dyslipidaemia in a primary care setting with associated triage of other high-risk groups to existing services.</i></p>
Partner organisation/s	<p><i>Sandwell and West Birmingham Hospitals NHS Trust</i></p> <p><i>Sanofi</i></p>
Project rationale	<p><i>The specific objectives of the project are:</i></p> <ul style="list-style-type: none"> • <i>Creation of a nurse led community lipid clinic within The Modality Group with clinical supervision provided by Consultant Chemical Pathologist at Sandwell and West Birmingham NHS Trust. *</i> • <i>Create and undertake a computer search which identifies high risk cardiovascular patients with elevated LDL-C to identify patients with cardiovascular disease and primary hypercholesterolaemia / mixed dyslipidaemia. *</i> • <i>Triage by Consultant Chemical Pathologist of the patients identified in order to direct them to the most appropriate clinic (Lipid, FH, Community Lipid or Cardiology) creating a clear integrated pathway for Primary Care. *</i> • <i>Proof of concept and reproducibility of a Community Lipid clinic.</i>
Project period	<p><i>Q4 2020 to Q4 2021</i></p>
Project objectives	<p>Patients</p> <ul style="list-style-type: none"> • <i>Increased diagnosis rate and improved management of high risk cardiovascular patients with elevated LDL-C.</i> • <i>Optimisation of treatment and lipid management</i> • <i>Improved access to specialised lipid service</i> • <i>Care closer to home</i> • <i>Patient empowerment and engagement in terms of their diagnosis and subsequent clinical management plan Support implementation of NICE CG181⁽¹⁾</i> <p>The NHS:</p> <ul style="list-style-type: none"> • <i>Development of a primary care service that could be commissioned elsewhere/across other PCN's.</i> • <i>Increased capacity of lipid service</i> • <i>Reduction in waiting time.</i> • <i>Alignment with NHS Long term plan ⁽²⁾ and CVDPrevent Audit in Primary Care.</i> • <i>Support implementation of NICE CG181⁽¹⁾</i>

	<p>Sanofi:</p> <ul style="list-style-type: none"> • <i>The project aims to increase the diagnosis rate and improved management of high risk cardiovascular patients with elevated LDL-C - Patients diagnosed with these conditions will be treated with cholesterol lowering medicines which may include Sanofi medicines for suitable patients in line with NICE TA393⁽³⁾ /TA394⁽⁴⁾ and or local / national guidelines</i> • <i>Demonstrates collaborative working and enhanced reputation with the NHS to the benefit of patients that identifies scalable solutions.</i> <p>The NHS and Sanofi: <i>An opportunity to document how joint working between Sandwell & West Birmingham Hospital Trust, Modality and Sanofi has improved the identification and management of patients with cardiovascular disease and primary hypercholesterolaemia / mixed dyslipidaemia. Potential scenarios for sharing best practice may include:</i></p> <ul style="list-style-type: none"> ○ <i>Case Studies to share best practice with the NHS</i> ○ <i>Presentations to various NHS organisations</i> ○ <i>Conference abstracts, posters and presentations</i> ○ <i>Publications e.g. TBD</i>
<p>Contact details</p>	<p><i>Professor Elizabeth Hughes - Consultant Chemical Pathologist and Deputy Medical Director- Sandwell & City Hospital Trust.</i> Elizabeth.hughes@hee.nhs.uk</p> <p><i>Fleur Chandler- Director of Patient Access, UK & Ireland.</i> 410 Thames Valley Park Drive, Reading, Berkshire. RG6 1PT. GB-MarketAccess@sanofi.com</p>